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High density lipoproteins (HDL) and 
apolipoprotein A-I (apoA-I) must leave the 
circulation and pass the endothelium to exert 
their atheroprotective actions in the arterial 
wall. We previously demonstrated that the 
transendothelial transport of apoA-I involves 
ATP-binding cassette transporter (ABC) A1 
and re-secretion of lipidated particles. 
Transendothelial transport of HDL is 
modulated by ABCG1 and the scavenger 
receptor BI (SR-BI). We hypothesize that 
apoA-I transport is started by the ABCA1-
mediated generation of a lipidated particle 
which is then transported by ABCA1-
independent pathways. To test this hypothesis 
we analysed the endothelial binding and 
transport properties of initially lipid-free as 
well as pre-lipidated apoA-I mutants. Lipid-
free apoA-I mutants with a defective carboxy-
terminal domain showed an 80% decreased 
specific binding and 90% decreased specific 
transport by aortic endothelial cells (ECs). 
After prior cell-free lipidation of the mutants 
the resulting HDL-like particles were 
transported through ECs by an ABCG1-
dependent but SR-BI-independent process. 
ApoA-I mutants with deletions of either the 
amino-terminus or both the amino- and 
carboxy-terminus showed dramatic increases 
in non-specific binding and transport but no 
specific binding or transport. Prior cell-free 
lipidation did not rescue these anomalies. Our 
findings of stringent structure-function 
relationships underline the specificity of 
transendothelial apoA-I transport and suggest 
that lipidation of initially lipid-free apoA-I is 
necessary but not sufficient for specific 
transendothelial transport. Our data also 
support the model of a two-step process for 
the transendothelial transport of apoA-I in 
which apoA-I is initially lipidated by ABCA1 
and then further processed by ABCA1-
independent mechanisms. 
 
Atherosclerosis is a progressive disease which is 
characterized by lipid accumulation in 
macrophages in the arterial wall and leads to 
complications like heart attacks and strokes (1). 
Low plasma levels of high density lipoprotein 
(HDL) cholesterol as well as apolipoprotein A-I 
(apoA-I) are associated with increased risk of 
coronary heart disease (2). 
Mature HDL particles are synthesized mainly in 
the liver and intestine by a multi-step process 
which is initiated by the binding of cellular 
phospholipids and cholesterol to initially lipid-
free apoA-I. This step requires the presence of 
the ATP-binding cassette transporter (ABC) A1 
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(3). Based on X-ray crystallography and 
computer modelling, most of the 243 amino acid 
residues of apoA-I are grouped in amphipathic 
alpha-helices, 11 or 2 × 11 amino acids in length 
(4-10), that embrace the carbon chains of several 
phospholipid molecules like a belt.  
Both HDL and apoA-I were found to exert 
multiple anti-atherogenic properties, for example 
on the function and viability of the endothelium, 
the cholesterol homoeostasis and inflammatory 
state of macrophages, lipoprotein oxidation, 
coagulation, and thrombosis (2,11). One major 
anti-atherogenic effect is the removal of excess 
cholesterol from macrophage foam cells of 
atherosclerotic lesions and its delivery to the 
liver for biliary excretion (12). 
To fulfill their atheroprotective actions in the 
subendothelial space of arteries, HDL or its 
precursor, lipid-poor apoA-I, have to leave the 
circulation and pass the endothelium. This 
cellular monolayer of the interior surface of 
blood vessels forms a semi-permeable barrier 
and regulates liquid and solute transport between 
intra- and extravascular compartments (13). 
Little is known on how plasma proteins 
including HDL and apoA-I cross this endothelial 
barrier and enter the vascular wall (14). 
Morphological, biochemical, and physiological 
studies have suggested both paracellular and 
transcellular transport of proteins through the 
intact endothelium. We previously demonstrated 
that the transendothelial transport of both HDL 
and apoA-I involves saturable and specific 
processes. Transport of HDL is modulated by 
ABCG1 and the scavenger receptor BI (SR-BI) 
(15) whereas the transendothelial transport of 
lipid-free apoA-I is modulated by ABCA1. 
After apical-to-basolateral transport though 
aortic endothelial cells (ECs) the initially lipid-
free apoA-I was recovered as a lipidated particle 
(16-17). From this observation and in analogy to 
similar observations on apoA-I and ABCA1 
mediated lipid efflux from macrophages (18-20), 
we hypothesize that the transendothelial 
transport of apoA-I is a two-step process. First a 
functional interaction between apoA-I and 
ABCA1 is required to generate a lipidated 
particle which is subsequently transported by 
ABCA1 independent processes. To test this 
hypothesis, we investigated the endothelial 
binding and transport properties of initially lipid-
free as well as pre-lipidated apoA-I mutants 
which have been previously well characterized 
for their capacity to induce ABCA1-dependent 
phospholipid and cholesterol efflux from 
macrophage cell lines and to form HDL both in 
vitro and in vivo (21). Specifically we compared 
recombinant wild-type (WT) apoA-I, two 
mutants with either a deletion (apoA-I(185-
243)) or multiple amino acid substitutions in the 
carboxy-terminal domain, which are both 
defective in eliciting ABCA1 mediated lipid 
efflux from macrophages, as well as three apoA-I 
mutants with deletions of either the amino-
terminus (apoA-I(1-59)) or midregional 
domains (apoA-I(144-165)) or both the amino- 
and carboxy-terminal domains (apoA-I(1-
59/185-243)), which have no or only slightly 
impaired lipid efflux capacity (22). Our data 
show that the carboxy-terminal ABCA1 
interaction domain of apoA-I is mandatory for 
the transendothelial transport of lipid-free apoA-I 
but not of pre-lipidated apoA-I particles and thus 
support the model of a two-step process for 
transendothelial apoA-I transport. 
 
Experimental Procedures 
 
Cell culture - ECs were isolated from bovine 
aortas as described previously (23) and cultured 
in Dulbecco's modified Eagle medium (DMEM) 
(Sigma) supplemented with 5% fetal calf serum 
(FCS) at 37°C in a humidified 5% CO2, 95% air 
incubator. 
 
Small interfering (si)RNA transfection - ECs 
were transfected with 100 nM Stealth small 
interfering (si)RNA against either ABCA1, 
ABCG1, ABCA1/ABCG1 or SR-BI and 34 nM 
BLOCK-iT fluorescent oligo (Invitrogen) as 
described previously (15). Binding and transport 
assays were conducted between 65 and 72 h after 
transfection. The efficiency of the silencing was 
evaluated by quantitative RT-PCR and Western 
blotting, as shown previously (15,17). 
 
Isolation of HDL and apoA-I from plasma - 
Human HDL (1.063<d<1.21 kg/l) was isolated 
from fresh normolipidemic plasmas of blood 
donors by sequential ultracentrifugation (24). 
The purity of the lipoprotein preparation was 
verified by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) in order to assure 
no contamination with LDL or albumin. Lipid-
free human plasma WT apoA-I was further 
purified from delipidated HDL as described 
previously (25)  
 
Production and isolation of recombinant 
apoA-I - Production of the recombinant WT 
apoA-I and of the apoA-I mutants (185-243), 
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(144-165), (1-59), and (1-59)/(185-243) 
was described previously (26), (22), (27), (28), 
(29). 
Generation of adenoviruses expressing the apoA-
I(L218A/L219A/V221A/L222A): The apoA-I 
gene lacking the BglII restriction site (that is 
present at nucleotide positions 181 of the 
genomic sequence relative to the ATG codon of 
the gene), was cloned into the pCDNA3.1 vector 
to generate the pCDNA3.1-apoA-I(ΔBglII) 
plasmid as described (30). This plasmid was used 
as a template to introduce the apoA-
I(L218A/L219A/V221A/L222A) mutations in 
apoA-I using the mutagenesis kit QuickChange® 
XL (Stratagene) and the mutagenic primers. The 
forward (F) and reverse (R) primers used are F: 
5’GGACCTCCGCCAAGGCGCGGCGCCCGC
GGCGGAGAGCTTCAAGGTC-3’ and R: 5’-
GACCTTGAAGCTCTCCGCCGCGGGCGCCG
CGCCTTGGCGGAGGTCC-3’ (sites of the 
mutagenesis are underlined). Following 18 
cycles of PCR amplification of the template 
DNA, the PCR product was treated with DpnI to 
digest plasmids containing methylated DNA in 
one or both of their strands. The reaction product 
consisting of plasmids containing newly 
synthesized DNA carrying the mutations of 
interest were used to transform competent XL-10 
blue bacteria cells (Stratagene). Ampicillin-
resistant clones were selected, and plasmid DNA 
was isolated from these clones and subjected to 
sequencing to confirm the presence of the point 
mutations. The 2.2 kb apoA-I inserts containing 
the apoA-I mutant was cloned into the pAdTrack 
CMV vector which was used to generate the 
adenoviral constructs by recombination with the 
Ad-Easy-1 helper virus in the bacteria cells BJ-
5183-pAD1(Stratagene), that contain the Ad-
Easy-1 helper virus. Correct clones were 
propagated in DH5a bacteria cells. The 
recombinant adenoviral constructs were 
linearized after incubation with PacI and used to 
transfect 911 cells. Following large-scale 
infection of human embryonic kidney 293 cell 
cultures, the recombinant adenoviruses were 
purified by two consecutive CsCl 
ultracentrifugation steps, dialyzed and titrated. 
The mutant protein was isolate from the culture 
medium of HTB-13 cells infected with the apoA-
I(L218A/L219A/V221A/L222A) expressing 
adenovirus as described (22,26). 
Lyophilized apoA-I mutants were dissolved in 5 
M Guanidiniumhydrochloride and dialysed 
against 0.01 M Tris-HCl pH 8, 0.15 M NaCl. 
The iodination was carried out by the same 
procedure as described before for WT apoA-I 
adjusted to pH 8 and the extensive dialysis was 
against 0.01 M Tris-HCl pH 8, 0.15 M NaCl. 
 
Radiolabeling of apoA-I - ApoA-I was labeled 
with 125I using the Iodo-Beads iodination reagent 
(Pierce) and Na125I (Hartmann Analytic) 
according to the manufacturer's instructions. In a 
typical reaction, we used 0.5 mCi of Na125I, 0.7 
mg of apoA-I, and two beads. Protein was 
separated from unincorporated 125I with a 
Sephadex G-25 column (Amersham Biosciences) 
followed by extensive dialysis (against 0.15 M 
NaCl, 0.3 mM EDTA, pH 7.4) to remove 
residual free iodine. The specific activity 
expressed as cpm/ng protein was calculated 
based on the protein concentration measured by 
the DC protein assay (Bio Rad) and the activity 
measured using a -counter (Perkin Elmer). 
Specific activities of 600–1200 cpm/ng protein 
were obtained. 
 
Preparation of reconstituted HDL (rHDL) - 
Discoidal rHDL particles were produced by the 
cholate dialysis method (18) and contained WT 
or mutant apoA-I, 2-oleoyl-1-palmitoyl-sn-
glycero-3 phosphocholine (POPC) (Sigma), and 
sodium cholate (Sigma) in a molar ratio of 
1/40/100 ((mutant) ApoA-I 1:40). Reconstituted 
HDL was iodinated as described above for apoA-
I. Electron microscopy analysis of the particles 
was performed as described (22). 
 
Binding and cell association assays - Binding 
and cell association assays with 125I-apoA-I or 
125I-rHDL were performed as described 
previously (16). ECs were incubated with the 
indicated concentrations of 125I-apoA-I or 125I-
rHDL without (total) or with (non-specific) a 40-
fold excess of the indicated competitor for 2 h at 
4°C (binding) or 1 h at 37°C (cell association). 
Specific binding/cell association was calculated 
by subtracting the values of non-specific 
binding/cell association from those of total 
binding/cell association. All experiments were 
performed at least as triplicates. 
 
Transport assays - Transport assays were 
performed as previously described (16). In brief, 
ECs were seeded 2 days in advance on inserts 
(0.4 m, BD Biosciences) precoated with 
collagen type I (BD Biosciences). Medium 
containing either 125I-apoA-I or 125I-rHDL at the 
indicated concentrations was added to the apical 
compartment together with (non-specific 
transport) or in the absence (total transport) of a 
40-fold excess of unlabeled apoA-I and rHDL, 
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respectively. After incubation for 60 min at 37°C 
the media of the basolateral compartment were 
collected to measure radioactivity. Specific 
transport was calculated by subtracting the 
values of non-specific transport from those of 
total transport. 
 
Gel filtration chromatography - The size of 
apoA-I and mutant apoA-I before and after 
transendothelial transport was analyzed by gel 
filtration chromatography as described (31). In 
brief transport assays were performed in 4 
transwell cell culture wells as described above. 
The media (2 ml) were isolated from the 
basolateral compartments, combined and 
concentrated to 50 l by centrifugal 
concentrators (Vivaspin 500, Sartorius Stedim 
Biotech). The concentrate was loaded onto a 
SuperdexTM 200 prep grade HiLoadTM 16/60 
column (GE-Healthcare) of an Akta fast-protein 
liquid chromatography (FPLC) system and 
eluted with Tris saline (0.01 M Tris, 0.15 M 
NaCl, 0.1 mM EDTA, pH 7.5) at a flow rate of 
1.5 mL/min. Fractions (0.5 mL) were collected 
and the amounts of transported radioactivity 
were determined using a Perkin Elmer -counter. 
 
Native agarose gel electrophoresis - Equal 
amounts of proteins were used for mobility 
analysis and were loaded on a 1% native agarose 
gel (0.05 M barbital buffer, pH 8.6). 
Electrophoresis was performed at 4°C. After that, 
the gel was stained with Coomassie (protein 
staining) and Sudan black (lipid staining) using 
standard protocols. 
 
Statistical analyses - The data for all 
experiments were analyzed using GraphPad 
Prism 5 software program. Comparisons between 
groups were performed using t-test methods. 
Experiments were routinely performed in 
triplicates or quadruplets. Each experiment 
shown is a representative of at least three similar 
experiments. If not indicated otherwise the data 
are graphically represented as means +/- SD. 
 
Results 
 
Binding and association of lipid-free apoA-I 
mutants to ECs - Initially we compared the 
endothelial binding properties of WT apoA-I 
either isolated from plasma or produced as a 
recombinant protein. ECs were incubated with 
radiolabeled lipid-free WT apoA-I at 4°C in the 
absence (total) or presence of a 40-fold excess of 
unlabelled plasma WT apoA-I (non-specific). 
The difference between the total and the non-
specific binding corresponds to the specific 
binding. The recombinant and plasma-derived 
WT isoproteins of apoA-I showed the same total 
and specific binding to ECs. Therefore, in further 
experiments, plasma WT apoA-I was used as a 
control to compare the behaviour of the different 
apoA-I mutants. 
The apoA-I(144-165) mutant showed similar 
total and specific binding to ECs as WT apoA-I. 
The two mutants with a defective carboxy-
terminal sequence, apoA-I(185-243) and apoA-
I(L218A/L219A/V221A/L222A), showed 50% 
and 80% decreases in total and specific 
endothelial binding, respectively (figure 1). In 
contrast, apoA-I(1-59) and apoA-I(1-
59/185-243), showed a dramatic 25-fold 
increase in total binding. The binding of apoA-
I(1-59) could not be competed by unlabelled 
WT apoA-I so that no specific binding could be 
recorded (figure 1). The calculated specific 
binding of apoA-I(1-59/185-243) did not 
differ from that of WT apoA-I . 
We repeated these experiments at 37°C where 
ligands are not only bound but also internalized 
by ECs (16,32) and therefore the absolute 
amount of cell associated radioactivity is higher. 
In principle we made the same observations as 
described for binding at 4°C: WT apoA-I from 
plasma, recombinant WT apoA-I, and apoA-
I(144-165) did not differ from each other 
whereas the apoA-I(185-243) and apoA-
I(L218A/L219A/V221A/L222A) mutants 
showed strongly reduced total and specific cell 
association and the apoA-I(1-59) and apoA-
I(1-59/185-243) mutants showed massively 
increased total cell association which could not 
be competed by WT apoA-I (data not shown). 
 
Transport of lipid-free apoA-I mutants 
through ECs - Next, we analysed the transport 
of the different apoA-I mutants though ECs 
cultivated in a transwell system. Radiolabeled 
lipid-free WT or mutant apoA-I was added to the 
apical side with or without 40-fold excess of 
unlabelled competitor (WT apoA-I). After 1 h 
incubation at 37°C, the medium of the 
basolateral compartment was collected to 
measure radioactivity. The specific transport was 
calculated as the difference between total 
transport (radioactivity after incubation without 
competitor) and non-specific transport 
(radioactivity after incubation with competitor). 
As shown in figure 2, specific transports of 
plasma WT apoA-I, recombinant WT apoA-I, 
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and apoA-I(144-165) were similar. In contrast, 
the specific transports of apoA-I(185-243) and 
apoA-I(L218A/L219A/V221A/L222A) were 
decreased by 90%. No specific transports could 
be calculated for apoA-I(1-59) and apoA-I(1-
59/185-243) mutants because both in the 
presence or absence of the competitor the same 
amounts of radioactivity were recovered in the 
basolateral compartment of the transwell cell 
culture dish.  
 
ApoA-I with mutations in the carboxy-
terminus is not lipidated after 
transendothelial transport - In previous studies 
we observed a change in particle size and 
electrophoretic mobility of lipid-free WT apoA-I 
after the transport through ECs which we 
interpreted as a result of lipidation (16-17). 
Therefore, we compared the particle sizes of WT 
apoA-I and the dysfunctional apoA-
I(L218A/L219A/V221A/L222A) mutant before 
and after transport through ECs (figure 3). After 
transport and recovery from the basolateral 
compartment WT apoA-I was fractionated by gel 
filtration into two peaks, one peak with identical 
elution volume (87.6 ml +/- 0.5 ml) and hence 
size of the starting material and one new peak 
with lower elution volume (72.6 ml +/- 0.5 ml) 
and hence larger particle size (figure 3A). By 
contrast, the comparison of the gel filtration 
profiles of the binding- and transport-defective 
apoA-I(L218A/L219A/V221A/L222A) mutant 
before and after incubation with ECs did not 
reveal the occurrence of any new peak (figure 
3B). Already before incubation with cells and 
hence in the lipid-free state, this mutant was 
eluted in two peaks, one with the size of WT 
apoA-I (87.6 ml +/- 0.5 ml) and one 
corresponding to larger particle size (77.1 ml +/- 
0.5 ml). The larger sized fraction of apoA-
I(L218A/L219A/V221A/L222A) has a higher 
elution volume than the fraction formed after 
transport of WT apoA-I and did not change after 
transport. We therefore assume that this fraction 
represents lipid-free aggregates of apoA-
I(L218A/L219A/V221A/L222A). 
 
Role of ABCA1, ABCG1, and SR-BI for 
binding, cell association, and transport of 
lipid-free WT apoA-I - Using specific siRNAs 
(15), we investigated the effects of ABCA1, 
ABCG1, and SR-BI knock-down alone and the 
silencing of both ABCA1 and ABCG1 together 
on endothelial binding, cell association, and 
transport of lipid-free WT apoA-I (figure 4). 
ABCA1, ABCG1, and SR-BI transcription were 
reduced by about 80 – 90% in cells transfected 
with specific siRNA. The remaining protein 
expression of ABCA1, ABCG1, and SR-BI after 
silencing was approximately 50% as assessed by 
Western blotting and already shown previously 
(15,17). Also as reported previously, knock-
down of ABCA1, but not ABCG1 or SR-BI 
reduced the binding of lipid-free WT apoA-I at 
4°C (figure 4A). The knockdown of ABCA1 and 
ABCG1 together revealed the same reduction of 
apoA-I binding as the single knock-down of 
ABCA1 by about 60%. At 37°C, suppression of 
ABCA1 and ABCG1 either individually or both 
together but not the knock-down of SR-BI 
diminished the cell association (figure 4B) and 
transendothelial transport of initially lipid-free 
apoA-I (figure 4C) by about 40%.  
These at first sight discrepant observations at 
4°C and 37°C could be explained by a previously 
proposed two-step model in which ABCA1-
mediated lipid-efflux generates a lipidated 
particle that secondarily interacts with ABCG1 
(18-20). To test this hypothesis we analysed the 
binding, association and transport of HDL 
reconstituted artificially with WT or mutant 
apoA-I. 
 
Interactions of rHDL with ECs – We first 
compared the binding (at 4°C) and association 
properties (at 37°C) of WT apoA-I in either the 
lipid-free or pre-lipidiated forms. The binding of 
lipid-free apoA-I was competed by rHDL to 
similar degree as by lipid-free apoA-I itself or 
native HDL (figure 5A). The binding of rHDL 
was not competed by lipid-free apoA-I but by 
both reconstituted and native HDL (figure 5A). 
Cell association experiments yielded similar 
findings. Endothelial cell association of lipid-free 
apoA-I was competed with 40-fold excesses of 
unlabeled apoA-I, lipidated apoA-I, or HDL to 
similar degree (figure 5B). Cell association of 
rHDL was competed with an excess of either 
rHDL or native HDL (figure 5B). By contrast to 
the binding experiment, we however observed 
that also lipid-free apoA-I competed the cell 
association of rHDL, although to less extent 
(about 35%) than rHDL or native HDL (about 
60%). These observations provide further 
evidence that at 37°C the lipidation of apoA-I by 
ABCA1 generates a lipidated particle which can 
then compete the cellular interaction of pre-
lipidated apoA-I. 
 
Binding and transport of reconstituted HDL 
containing WT apoA-I or apoA-
I(L218A/L219A/V221A/L222A) – Next, we 
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exploited the apoA-
I(L218A/L219A/V221A/L222A) mutant with 
defects in ABCA1-mediated lipid-efflux as well 
as specific endothelial binding and transport to 
test the hypothesis that transendothelial transport 
of lipid-free apoA-I occurs by a two-step-
mechanism where apoA-I is first lipidated by 
ABCA1-dependent lipid-efflux to then undergo 
ABCA1-independent transport through ECs. We 
first lipidated WT apoA-I or apoA-
I(L218A/L219A/V221A/L222A). The lipidation 
and resulting particle formation was verified by 
native agarose gel electrophoresis and electron 
microscopy. Both WT apoA-I and apoA-
I(L218A/L219A/V221A/L222A) formed 
particles which had a higher electrophoretic 
mobility than the respective lipid-free 
apolipoproteins. rHDL containing apoA-
I(L218A/L219A/V221A/L222A) were slightly 
less negatively charged than rHDL containing 
WT apoA-I (figure 6A). In addition, the Sudan 
black staining of the agarose gel, clearly reveals 
the lipidation of both WT apoA-I and apoA-
I(L218A/L219A/V221A/L222A). After lipid 
staining the bands containing rHDL with WT or 
mutant apoA-I were similarly intense (figure 6B). 
Electron microscopy revealed that both WT 
apoA-I and apoA-I(L218A/L219A/V221A/ 
L222A) formed discoidal particles (figure 6C).  
We then used the pre-lipidated particles to 
perform binding and transport studies. Neither 
the specific binding (figure 6D) nor the specific 
transport (figure 6E) differed between particles 
containing either WT apoA-I or the mutant 
apoA-I(L218A/L219A/V221A/L222A). Thus 
pre-lipidation can overcome the binding and 
transport defects of the dysfunctional apoA-
I(L218A/L219A/V221A/L222A) mutant. These 
findings corroborate the hypothesis that 
lipidation of apoA-I is necessary for specific 
transcytosis. 
 
Binding and transport of reconstituted HDL 
containing apoA-I(1-59) and apoA-I(1-
59/185-243) - We then investigated the effects 
of prior cell-free lipidation on binding and 
transport of the two apoA-I mutants which in the 
lipid-free form showed excessive non-specific 
endothelial binding and transport, namely apoA-
I(1-59) and apoA-I(1-59/185-243). After 
cholate dialysis with POPC in a molar ratio of 
1:40, both mutant rHDL particles showed higher 
electrophoretic mobility than the respective lipid-
free apolipoproteins (figure 7A). The efficacy of 
lipidation was further confirmed by lipid staining 
of the agarose gel (figure 7B). The two mutant 
rHDL particles however differed from each other 
and from normal rHDL by electrophoretic 
mobility (figures 7A and 7B). Both mutants 
formed discoidal particles (figure 7C). With 
these lipidated mutants we performed binding 
and transport studies. We used native HDL as the 
competitor, because reconstituted and native 
HDL competed equivalently (see figure 5). As 
shown in figure 7D, specific binding of the 
lipidated WT apoA-I was about 60 % of the 
specific binding of lipid-free WT apoA-I. 
However, pre-lipidated apoA-I(1-59) and pre-
lipidated apoA-I(1-59/185-243) showed 4-
fold and 8-fold higher total binding than pre-
lipidated WT apoA-I. In contrast to lipidated WT 
apoA-I, it was not possible to compete this 
binding with excess HDL indicating that these 
mutants keep their very high non-specific 
endothelial binding properties also after pre-
lipidation. In contrast to apoA-
I(L218A/L219A/V221A/L222A), pre-lipidation 
of either apoA-I(1-59) or apoA-I(1-59/185-
243) did not rescue their defective specific 
transendothelial transport (figure 7E). These 
findings suggest that lipidation of initially lipid-
free apoA-I is not sufficient for the specific 
transport through ECs of the apoA-I(Δ1-59) or 
apoA-I(Δ1-59/Δ185-243) mutants. 
 
Role of ABCA1, ABCG1, and SR-BI for 
transport of rHDL - To analyze which of the 
known apoA-I/HDL binding proteins are 
participating in the transport of pre-lipidated 
apoA-I we used siRNAs to suppress ABCA1, 
ABCG1 or SR-BI. Knock down of ABCG1 and 
SR-BI but not of ABCA1 decreased the specific 
transendothelial transport of pre-lipidated WT 
apoA-I (figure 8A) and pre-lipidated apoA-
I(L218A/L219A/V221A/L222A) (figure 8B). 
The reduction of the transport capacity of 
lipidated apoA-I(L218A/L219A/V221A/L222A) 
by knock down of ABCG1 or SR-BI was smaller 
(-44% +/-7 %) compared to lipidated WT apoA-I 
(-60% +/- 15%). 
 
Discussion 
 
We recently provided several arguments that the 
transendothelial transport of apoA-I and HDL 
occurs by specific transport rather than 
unspecific filtration: 1) a considerable proportion 
of apoA-I and HDL transport is temperature 
sensitive and can be competed by excess of 
apoA-I and HDL, respectively, but not with 
albumin or LDL (15-16). 2) The specific fraction 
of transendothelial apoA-I transport can be 
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inhibited by knock-down of ABCA1 and leads to 
the secretion of lipidated particles (17). 3) The 
specific fraction of transendothelial HDL 
transport can be reduced by knock-down of 
ABCG1 or SR-BI and leads to the secretion of an 
HDL particle of reduced size (15). The findings 
of this study further support the specificity of 
transendothelial apoA-I and HDL transport by 
stringent structure-function-relationships for 
apoA-I that reveals the importance of the 
carboxy-terminal apoA-I domain for this 
process: 
 
1. Both the deletion of the carboxy-terminus of 
apoA-I as well as amino acid substitutions within 
the carboxy-terminus of apoA-I nearly abolished 
the specific endothelial binding and 
transendothelial transport of apoA-I (figure 1, 2). 
The deletion of the carboxy-terminus was 
previously shown to be defective in inducing 
ABCA1-mediated phospholipid and cholesterol 
efflux from macrophages and to form nascent 
and mature HDL particles in vivo (22,26,33). 
Also in our endothelial transwell cell culture 
model both apoA-I(185–243) and apoA-
I(L218A/L219A/V221A/L222A) failed to form 
HDL-like particles although only the specific but 
not the non-specific fraction of transendothelial 
transport was abolished.  
 
2. The deletion of the amino-terminus of apoA-I, 
alone or together with the carboxy-terminus, 
tremendously increased the non-specific binding 
of apoA-I(1-59) and apoA-I(1-59/185-243), 
respectively, and interfered with the specific 
transport of these mutants both in the lipid-free 
and lipidated forms (figure 1, 2, 7). Interestingly, 
these mutants were previously found to elicit 
normal or only moderately decreased ABCA1-
dependent lipid efflux from macrophages and 
similar mutations (apoA-I(1-41) and apoA-
I(1-41/185-243)) promoted biogenesis of 
HDL particles in vivo (22). However, in the large 
background of excessive cellular non-specific 
binding to cells, we may have overlooked 
specific components of transendothelial transport. 
In fact, the double deletion mutant (apoA-I(1-
59/185-243) but not the amino-terminal 
deletion apoA-I(1-59) mutant showed more 
than normal specific binding to ECs (figure 1). 
Alternatively, the deletion of the amino-terminus 
and especially both the amino-terminus and 
carboxy-terminus may expose a midregional 
domain of prototypic anti-parallel amphipathic 
alpha-helices which has a very high affinity to 
lipids (34). According to a model proposed by 
Phillips et al. this central domain of apoA-I may 
bind very efficiently and solubilise lipids of 
plasma membranes which are generated by 
ABCA1 (35). In fact, pretreatment of ECs with 
cyclosporine A, which was shown by us and 
others to trap dysfunctional ABCA1 on the cells 
surface (17,36), reduced the excessive non-
specific binding of apoA-I(1-59) and apoA-
I(1-59/185-243) (data not shown). 
Furthermore, it has been shown that the amino-
terminal deletion destabilizes apoA-I and leads to 
unfolding of the alpha-helices in the carboxy-
terminal domain which is responsible for specific 
interactions with ABCA1 (37-38). 
 
3. The deletion of a central domain in apoA-
I(144-165) interfered neither with specific 
binding nor specific transendothelial transport 
(figure 1, 2). This mutant was previously found 
to behave like WT apoA-I in mediating ABCA1 
dependent lipid efflux but to be defective in 
lecithin:cholesterol acyl transferase (LCAT) 
activation (22,39-40).  
 
Taken together our data further emphasize the 
importance of ABCA1 as a rate limiting step for 
transendothelial apoA-I transport. Several 
authors have provided evidence for a physical 
interaction of apoA-I with ABCA1 (22,41). The 
formation of a high affinity complex of apoA-I 
with ABCA1 is thought to play an important 
regulatory first step in ABCA1-mediated lipid 
efflux by stabilizing ABCA1 in the plasma 
membrane and eliciting signalling events which 
enrich distinct plasma membranes with lipids for 
facilitated removal by apoA-I (39,42-43). 
However, the signalling events elicited by apoA-
I/ABCA1 interaction have also been related to 
other cellular responses such as cell migration 
and endocytosis (44-45). As the consequence, the 
defective transendothelial transport of apoA-I 
mutants with a missing or dysfunctional carboxy-
terminal ABCA1-interaction domain may be 
principally explained by disturbances in different 
downstream events. Our present results shed 
some light into these different scenarios:  
By using gel filtration we here corroborated our 
previous finding that transendothelial transport 
leads to the secretion of a lipidated particle on 
the basolateral side (16). The apoA-
I(L218A/L219A/V221A/L222A) mutant, which 
shows strongly reduced specific but normal non-
specific transendothelial transport (data not 
shown), was not recovered as a lipidated particle 
(figure 3). However, after prior cell-free 
lipidation the carboxy-terminal apoA-I mutant 
 at SM
AC Consortium
 - University of Zürich, on January 7, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
 8
was normally bound and transported by ECs 
(figure 6). This finding suggests that the 
transendothelial transport of apoA-I is initiated 
by ABCA1-mediated lipidation of apoA-I and 
followed by ABCA1-independent transport steps. 
These downstream pathways may be shared with 
the transport of HDL, since knock-down of 
ABCG1 or SR-BI inhibited the specific transport 
of native HDL (15) as well as rHDL containing 
either WT apoA-I or apoA-
I(L218A/L219A/V221A/L222A) (figure 8). In 
agreement with normal binding of rHDL 
containing apoA-
I(L218A/L219A/V221A/L222A) ldlA-7 cells 
expressing SR-BI were previously found to bind 
rHDL containing apoA-I(185-243) with similar 
affinity as rHDL with WT apoA-I (46). In 
general our findings resemble similar findings 
and models on the interaction of ABCA1, 
ABCG1, and SR-BI in cholesterol efflux: 
ABCA1-mediated lipid efflux to initially lipid-
free apoA-I generates particles which then 
interact with ABCG1 and SR-BI for enhanced 
cholesterol efflux (18-20).  
Interestingly, the lipidation did not restore the 
abnormal binding and transport of apoA-I(1-
59) or apoA-I(1-59/185-243 (figure 7). 
Although less intense than in the lipid-free form, 
also in the pre-lipidated form these mutants 
showed strongly enhanced binding to ECs and 
not-recordable specific binding and 
transendothelial transport. This suggests that the 
amino-terminal domain is an important structural 
determinant for specific endothelial binding and 
transendothelial transport of HDL. Previously, 
rHDL containing apoA-I(1-59/185-243) were 
reported to be unable to compete for rHDL 
binding to ldlA-7 cells expressing the murine 
SR-BI receptor (27). Indirectly, this supports the 
importance of SR-BI as a rate limiting factor for 
endothelial binding and transport of HDL. 
However, rHDL containing the apoA-I(1-59) 
mutant, which in our hands is also defective in 
endothelial binding and transport, was reported 
to bind with normal affinity to SR-BI 
overexpressing ldlA-7 cells (27,46). The reason 
for this discrepancy remains unclear. 
In summary, the distinct binding and transport 
defects of apoA-I mutants provide further 
support that transendothelial transport of apoA-I 
and HDL requires defined structural domains and 
hence involves specific protein/protein 
interactions rather than unspecific filtration. 
These experiments also support the importance 
of ABCA1 for the transport of lipid-free apoA-I 
and provided first hints on the underlying 
mechanisms: By lipidating apoA-I ABCA1 helps 
to generate a particle which is then processed by 
ABCA1-independent mechanisms for 
transendothelial transport. Like the transport of 
mature HDL, the processing of these nascent 
HDL particles appears to involve ABCG1 and 
SR-BI. 
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ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; SR-BI, 
scavenger receptor BI; WT, wild-type; ECs, aortic endothelial cells; rHDL, reconstituted HDL 
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Figure Legends 
 
Figure 1. Binding of WT and mutant apoA-I to ECs. Cells were cultured in 12- well dishes for 48 
hours. Then, after pre-chilling on ice, the cells were incubated with 5 μg/ml of the indicated WT or 
mutant  125I-apoA-I isoform in the absence (total) or presence (non-specific) of a 40-fold excess of 
unlabeled WT apoA-I. After 2 hours of incubation at 4°C, the specific binding was determined by 
subtracting the values of non-specific binding from those of total binding. The results are represented 
as means ± SD of at least 3 individual experiments. 
 
Figure 2. Transport of WT and mutant apoA-I through ECs. Cells were cultured on membrane 
inserts 48 hours before the assay. 5 μg/ml of the indicated WT or mutant  125I-apoA-I isoform as well 
as no or a 40-fold excess of unlabeled WT apoA-I were added to the apical compartment. The media 
of the basolateral compartments of the transwell chambers were collected after incubation for 1 hour at 
37°C to measure the radioactivity. Specific transport from the apical to the basolateral compartment 
was calculated as the difference in radioactivity between the samples with (non-specific transport) and 
without (total transport) excess of WT apoA-I. The results are represented as means ± SD of at least 3 
individual experiments. 
 
Figure 3. Particle size of WT apoA-I and apoA-I(L218A/L219A/V221A/L222A) before and after 
transport through ECs. The transport experiment was performed as described in figure 3, however 
only in the absence of excess unlabeled apoA-I. Both lipid-free apoA-I not incubated with cells and 
the material in the basolateral compartment were fractionated by gel filtration. (A) WT 125I-apoA-I, 
(B) 125I-apoA-I(L218A/L219A/V221A/L222A). 
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Figure 4. Role of ABCA1, ABCG1, and SR-BI for binding, cell association, and transport of WT 
apoA-I. ECs were transfected with specific siRNA against ABCA1, ABCG1, SR-BI, not coding 
siRNA and mock (not transfected cells). 65 – 72 hours after transfection, binding (A), cell association 
(B), and transport assays (C) were performed as described above. *P<0.05 **P<0.01, ***P<0.001, ns 
not significantly different compared to not transfected cells. 
 
Figure 5. Cross-competition of lipid-free and lipidated apoA-I. Binding (A) and cell association (B) 
assays were performed. ECs were incubated with 5 g/ml of 125I-apoA-I or 125I-rHDL containing WT 
apoA-I for 2 hours at 4°C (binding) or for 1 hour at 37°C (cell association) in the absence (total) or 
presence of a 40-fold excess of the indicated competitor.  
 
Figure 6. Binding and transport of reconstituted HDL (rHDL) containing WT apoA-I and apoA-
I(L218A/L219A/V221A/L222A). The lipidation of the rHDL particles was performed by the cholate 
dialysis method and the particle formation was analysed by native agarose gel electrophoresis stained 
with Coomassie for proteins (A) and with Sudan black for lipids (B). Electron microscopy of the 
formed particles was performed (C). (D) Specific binding at 4°C of 10 g/ml 125I-rHDL particles 
containing either WT apoA-I or apoA-I(L218A/L219A/V221A/L222A). (E) Specific Transport of 10 
g/ml 125I-rHDL particles containing either WT apoA-I or apoA-I(L218A/L219A/V221A/L222A) 
through a monolayer of ECs. 
 
Figure 7. Binding and transport of rHDL containing WT apoA-I, apoA-I(1-59), and apoA-I(1-
59/185-243). Lipidation was verified native agarose gel electrophoresis stained with Coomassie for 
proteins (A) and with Sudan black for lipids (B) and by electron microscopy (C). (D) Binding at 4°C 
of 10 g/ml 125I-rHDL containing WT apoA-I, apoA-I(1-59), or apoA-I(1-59/185-243). (E) 
Specific transport through a monolayer of ECs of 10 g/ml 125I rHDL containing WT apoA-I, apoA-
I(1-59), or apoA-I(1-59/185-243). 
 
Figure 8. Role of ABCA1, ABCG1, and SR-BI in the transport of rHDL containing WT apoA-I 
or apoA-I(L218A/L219A/V221A/L222A). ECs were transfected with siRNA coding for ABCA1, 
ABCG1, SR-BI and not coding siRNA. 65 – 72 hours after transfection transport assays were 
performed. ECs were incubated with 10 g/ml of 125I-rHDL for 1 hour in the absence or presence of a 
40-fold excess of unlabeled rHDL. Specific transport was calculated by subtracting the values of non-
specific transport from those of total transport. (A) Specific transport of rHDL containing WT apoA-I. 
(B) Specific transport of rHDL containing apoA-I(L218A/L219A/V221A/L222A). **P<0.01, 
***P<0.001, ns not significantly different compared to not transfected cells. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
 
A B
C
 
 
 at SM
AC Consortium
 - University of Zürich, on January 7, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
 16
Figure 5 
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Figure 6 
 
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
apoA-I 1:40 L218A/L219A  V221A/L222A 1:40
A B
C
D E
1 – HDL
2 – lipid-free apoA-I
3 – apoA-I/POPC 1:40
4 – lipid-free L218A/L219A/V221A/L222A
5 – L218A/L219A/V221A/L222A/POPC 1:40
1      2     3      4    5   1      2     3      4    5   
0.0
20.0
40.0
60.0
80.0
100.0
120.0
apoA-I 1:40 L218A/L219A  V221A/L222A 1:40
b
o
u
n
d
 1
25
I-L
ig
an
d
 (%
)
tr
an
sp
o
rt
ed
 1
25
I-L
ig
an
d
 (%
)
-
+
 
 
 at SM
AC Consortium
 - University of Zürich, on January 7, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
 18
Figure 7 
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Figure 8 
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